medigraphic.com

2020, Number 3

<< Back Next >>

Rev Fac Med UNAM 2020; 63 (3)

Human Metapneumovirus: Epidemiology and Possible Prophylactic Treatments

Solís-Rodríguez M, Alpuche-Solís ÁG, Tirado-Mendoza RG

Language: Spanish
References: 37
Page: 7-18
PDF size: 1914.71 Kb.


ABSTRACT

In 2001 in the Netherlands, Human metapneumovirus (hMPV) was identified as a “new” etiologic agent causing acute respiratory infections in children younger than 5 years old; however, it has also been isolated in the elderly and immunocompromised people. This virus is considered the second etiological agent in acute diseases of the respiratory tract. Currently, the estimated cost of IRAs in our country is of 9,000 USD per inpatient.
hMPV is a member of the genus Metapneumovirus, family Pneumoviridae, and it belongs to the order Mononegavirales that is part of the negative single-stranded ribonucleic acid (RNA) virus, consisting of eight genes ordered: 3’-N-P-M-FM2- SH-G-L-5 ‘, and which encodes for 9 proteins. Of these proteins, the F fusion glycoprotein is highly conserved in the genus Metapneumovirus, and is the major antigenic determinant, and because an approved vaccine doesn’t exist, it has been used as a candidate epitope for the design of a vaccine that confers host immunity or as a therapeutic target in the creation of antiviral peptides that inhibit the fusion of the virus to its target cell and to avoid infection in subjects at high risk of contagion since there is currently none accepted by COFEPRIS as a prophylactic treatment against hMPV.


REFERENCES

  1. Márquez-Escobar VA, Tirado-Mendoza R, Noyola DE, Gutiérrez-Ortega A, Alpuche-Solís AG. HRA2pl peptide: a fusion inhibitor for human metapneumovirus produced in tobacco plants by transient transformation. Planta. 2015;242(1):69-76.

  2. Esposito S, Mastrolia MV. Metapneumovirus infections and respiratory complications. Semin Respir Crit Care Med. 2016;37(4):512-22.

  3. Panda S, Mohakud NK, Pena L, Kumar S. Human metapneumovirus: review of an important respiratory pathogen. Int J Infect Dis. 2014;25:45-52.

  4. INEGI INdEyG. Principales causas de mortalidad por residencia habitual, grupos de edad y sexo del fallecido. 2016; Consulta de resultados. Tabuladores básicos [Internet].

  5. Wei Y, Zhang Y, Cai H, Mirza AM, Iorio RM, Peeples ME, et al. Roles of the putative integrin-binding motif of the human metapneumovirus fusion (F) protein in cell-cell fusion, viral infectivity, and pathogenesis. J Virol. 2014;88(8):4338-52.

  6. ICTV. International Committe on Taxonomy of Viruses 2017. Disponible en: https://talk.ictvonline.org/

  7. Wei HY, Tsao KC, Huang CG, Huang YC, Lin TY. Clinical features of different genotypes/genogroups of human metapneumovirus in hospitalized children. J Microbiol, Immunol Infect. 2013;46(5):352-7.

  8. Papenburg J, Hamelin ME, Ouhoummane N, Carbonneau J, Ouakki M, Raymond F, et al. Comparison of risk factors for human metapneumovirus and respiratory syncytial virus disease severity in young children. J Infect Dis 2012;206(2):178-89.

  9. Hodinka RL. Respiratory RNA viruses. Microbiol Spectrum. 2016;4(4).

  10. Skiadopoulos MH, Biacchesi S, Buchholz UJ, Riggs JM, Surman SR, Amaro-Carambot E, et al. The two major human metapneumovirus genetic lineages are highly related antigenically, and the fusion (F) protein is a major contributor to this antigenic relatedness. J Virol 2004;78(13): 6927-37.

  11. Céspedes PF, Palavecino CE, Kalergis AM, Bueno SM. Modulation of host immunity by the human Metapneumovirus. Clin Microbiol Rev. 2016;29(4):795-818.

  12. Wen X, Pickens J, Mousa JJ, Leser GP, Lamb RA, Crowe JE, Jr., et al. A Chimeric Pneumovirus fusion protein carrying neutralizing epitopes of both MPV and RSV. PloS one. 2016;11(5):e0155917.

  13. Melero JA, Mas V. The Pneumovirinae fusion (F) protein: A common target for vaccines and antivirals. Virus Res. 2015;209:128-35.

  14. Connolly SA, Leser GP, Yin HS, Jardetzky TS, Lamb RA. Refolding of a paramyxovirus F protein from prefusion to postfusion conformations observed by liposome binding and electron microscopy. P Natl Acad Sci USA. 2006;103(47):17903-8.

  15. Edwards KM, Zhu Y, Griffin MR, Weinberg GA, Hall CB, Szilagyi PG, et al. Burden of human metapneumovirus infection in young children. N Engl J Med. 2013; 368(7):633-43.

  16. Diaz J, Morales-Romero J, Pérez-Gil G, Bedolla-Barajas M, Delgado-Figueroa N, García-Roman R, et al. Viral coinfection in acute respiratory infection in Mexican children treated by the emergency service: A cross-sectional study. Ital J Pediatr. 2015;41:33.

  17. Noyola DE, Alpuche-Solís AG, Herrera-Díaz A, Soria- Guerra RE, Sánchez-Alvarado J, López-Revilla R. Human metapneumovirus infections in Mexico: epidemiological and clinical characteristics. J Med Microbiol. 2005; 54(Pt 10):969-74.

  18. Kurskaya O, Ryabichenko T, Leonova N, Shi W, Bi H, Sharshov K, et al. Viral etiology of acute respiratory infections in hospitalized children in Novosibirsk City, Russia (2013 - 2017). PloS one. 2018;13(9):e0200117. Epub 2018/09/19.

  19. Meena JP, Brijwal M, Seth R, Gupta AK, Jethani J, Kapil A, et al. Prevalence and clinical outcome of respiratory viral infections among children with cancer and febrile neutropenia. Pediatr Hemat Oncol. 2019;36(6):330-43. Epub 2019/09/13.

  20. Gamino-Arroyo AE, Moreno-Espinosa S, Llamosas-Gallardo B, Ortiz-Hernández AA, Guerrero ML, Galindo- Fraga A, et al. Epidemiology and clinical characteristics of respiratory syncytial virus infections among children and adults in Mexico. Influenza Other Resp. 2017;11(1):48-56. Epub 2016/07/22.

  21. Wong-Chew RM, Espinoza MA, Taboada B, Aponte FE, Arias-Ortiz MA, Monge-Martínez J, et al. Prevalence of respiratory virus in symptomatic children in private physician office settings in five communities of the state of Veracruz, Mexico. BMC Research Notes. 2015;8:261. Epub 2015/06/26.

  22. Papenburg J, Carbonneau J, Isabel S, Bergeron MG, Williams JV, De Serres G, et al. Genetic diversity and molecular evolution of the major human metapneumovirus surface glycoproteins over a decade. J Clin Virol Off Publ Pan Am Soc Clin Virol. 2013;58(3):541-7.

  23. Anderson EJ, Simoes EA, Buttery JP, Dennehy PH, Domachowske JB, Jensen K, et al. Prevalence and characteristics of human Metapneumovirus infection among hospitalized children at high risk for severe lower respiratory tract Infection. J Pediatr Infec Dis Soc. 2012;1(3):212-22.

  24. Vargas SO, Kozakewich HP, Perez-Atayde AR, McAdam AJ. Pathology of human metapneumovirus infection: insights into the pathogenesis of a newly identified respiratory virus. Pediatr Develop Pathol: Off J Soc Pediatr Pathol Paediatr Pathol Soc. 2004;7(5):478-86; discussion 21. Epub 2004/11/18.

  25. Cox RG, Williams JV. Breaking in: human metapneumovirus fusion and entry. Viruses. 2013;5(1):192-210. Epub 2013/01/18.

  26. Wolf JM, Gregianini TS, Seadi CM, Tumioto GL, Dambros BP, Lehmann FK, et al. Performance of direct immunofluorescence assay for the detection of human metapneumovirus under clinical laboratory settings. Rev Soc Bras Med Trop. 2015;48(6):762-4.

  27. Zhang D, Feng Z, Zhao M, Wang H, Wang L, Yang S, et al. Clinical evaluation of a single-tube multiple RTPCR assay for the detection of 13 common virus types/ subtypes associated with acute respiratory infection. PloS one. 2016;11(4):e0152702.

  28. Norma Oficial Mexicana NOM-031-SSA2-1999, Para la atención a la salud del niño. (1999).

  29. Romero Feregrino R, Romero Feregrino R, Mora Magaña I, Romero Cabello R, González Saldaña N. Diagnóstico de Metapneumovirus humano. Revisión sistemática de la literatura. Rev Enf Infecc Ped. 2013; XXVI(103).

  30. Cox RG, Mainou BA, Johnson M, Hastings AK, Schuster JE, Dermody TS, et al. Human Metapneumovirus is capable of entering cells by fusion with endosomal membranes. PLoS Pathog. 2015;11(12):e1005303.

  31. Biacchesi S, Skiadopoulos MH, Yang L, Lamirande EW, Tran KC, Murphy BR, et al. Recombinant human Metapneumovirus lacking the small hydrophobic SH and/or attachment G glycoprotein: deletion of G yields a promising vaccine candidate. J Virol. 2004;78(23):12877-87.

  32. Levy C, Aerts L, Hamelin ME, Granier C, Szecsi J, Lavillette D, et al. Virus-like particle vaccine induces crossprotection against human metapneumovirus infections in mice. Vaccine. 2013;31(25):2778-85.

  33. Schuster JE, Williams JV. Human Metapneumovirus. Microbiol Spectr. 2014;2(5).

  34. Skiadopoulos MH, Biacchesi S, Buchholz UJ, Amaro- Carambot E, Surman SR, Collins PL, et al. Individual contributions of the human metapneumovirus F, G, and SH surface glycoproteins to the induction of neutralizing antibodies and protective immunity. Virology. 2006; 345(2):492-501. Epub 2005/11/23.

  35. Hastings AK, Gilchuk P, Joyce S, Williams JV. Novel HLA-A2-restricted human metapneumovirus epitopes reduce viral titers in mice and are recognized by human T cells. Vaccine. 2016;34(24):2663-70.

  36. Ortega-Berlanga B, Musiychuk K, Shoji Y, Chichester JA, Yusibov V, Patino-Rodriguez O, et al. Engineering and expression of a RhoA peptide against respiratory syncytial virus infection in plants. Planta. 2016;243(2):451-8.

  37. Deffrasnes C, Hamelin ME, Prince GA, Boivin G. Identification and evaluation of a highly effective fusion inhibitor for human metapneumovirus. Antimicrob Agents Chemother. 2008;52(1):279-87.




2020     |     www.medigraphic.com